KRAS and colorectal carcinoma: Misale et al. demonstrated, for the first time, that KRAS mutations are frequent drivers of acquired resistance to cetuximab in CRC, and indicated that the emergence of KRAS mutant clones can be detected, non-invasively, months prior to radiographic progression [72].